Miebo Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Miebo prescription, you might be wondering: is there an official Miebo shortage? The short answer is no — but that doesn't mean access is easy. Here's everything you need to know about Miebo availability in 2026.

Is Miebo in a Shortage in 2026?

As of 2026, Miebo (perfluorohexyloctane) is NOT listed on the FDA's official drug shortage database. There is no manufacturing shortage, no supply disruption reported by Bausch + Lomb, and no ASHP (American Society of Health-System Pharmacists) shortage alert. Bausch + Lomb generated $172 million in Miebo sales in its first full year (2024), exceeding projections of $95 million — production capacity is clearly in place.

So why do patients report difficulty filling their prescriptions? The answer comes down to distribution, pharmacy stocking practices, and insurance coverage — not a production shortage.

Why Some Patients Experience Miebo Access Problems

Access challenges with Miebo stem from several compounding factors:

• Brand-only drug, no generic: Without a generic, every prescription must be the brand-name product retailing at $800–$1,200+ per bottle.
• Inconsistent retail stocking: Many retail pharmacies don't keep high-cost specialty ophthalmic drugs in routine inventory unless local demand is established.
• Prior authorization requirements: Some insurance plans require PA before covering Miebo, which can delay filling.
• Distribution via BlinkRx: Bausch + Lomb routes many Miebo prescriptions through BlinkRx digital pharmacy, which may reduce the incentive for retail pharmacies to stock it.

Miebo's Coverage and Availability Timeline

Here's how Miebo's availability has evolved since FDA approval:

• May 2023: FDA approves Miebo — first prescription eye drop targeting tear evaporation.
• Late 2023: Commercially available; BlinkRx partnership launches.
• 2024: $172M in U.S. sales in first full year. Coverage grows to ~75% of commercial plans, ~65% of Medicare Part D.
• January 2025: Miebo achieves best-in-class formulary coverage on commercial and Medicare Part D plans, per the manufacturer.
• 2025: Bausch + Lomb raises price approximately 4% in 2025, per drug-price tracking firm 46brooklyn.
• 2026: No shortage. Coverage remains broad. Still no generic. Access remains uneven at retail level.

What Patients Can Do Right Now

If your pharmacy doesn't have Miebo, here are your immediate options:

1. Use medfinder: medfinder calls pharmacies near you to check which ones can fill your Miebo prescription.
2. Request BlinkRx delivery: Ask your prescriber to e-prescribe to BlinkRx for nationwide free delivery.
3. Activate the MIEBO MySavings card: Eligible commercially insured patients may pay as little as $0 copay. Not valid for Medicare/Medicaid patients.
4. Fight a PA denial: Ask your prescriber to submit a Letter of Medical Necessity. BlinkRx also assists with prior authorization.
5. Request samples: Your eye doctor may have Miebo samples to bridge you while access issues resolve.

Should I Switch to an Alternative?

Only if your prescriber recommends it. Miebo targets evaporative dry eye through a unique mechanism — no other FDA-approved drug works the same way. Switching to an anti-inflammatory like Restasis or Xiidra may be effective if your dry eye has an inflammatory component, but it won't directly address tear evaporation. For a full comparison of alternatives, see our article on alternatives to Miebo.

The Bottom Line

There is no Miebo shortage in 2026. Access challenges are real but solvable — primarily through BlinkRx mail delivery, medfinder's pharmacy search, and appropriate use of the manufacturer's savings programs. Don't give up on Miebo if it's been working for you. The right help is available.